We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




First-of-Its-Kind Study Establishes Pediatric Reference Intervals for Common Cardiovascular Disease Tests

By LabMedica International staff writers
Posted on 13 Apr 2023
Print article
Image: A breaking research could improve cardiac care for children (Photo courtesy of Freepik)
Image: A breaking research could improve cardiac care for children (Photo courtesy of Freepik)

Numerous pediatric hospitals have begun utilizing two cardiac tests, high-sensitivity cardiac troponin (hs-cTn) and N-terminal pro B-type natriuretic peptide (NT-proBNP), which measure levels of proteins cTn I or T and NT-proBNP respectively. Recent research indicates that these tests may enhance care for children with various conditions, including congenital heart disease, heart failure, and multi-system organ failure due to sepsis. However, a significant limitation is the lack of established pediatric reference intervals for hs-cTn and NT-proBNP. These intervals, which account for age, developmental stage, ethnicity, and gender, are crucial for accurate test interpretation, as their absence can lead to misdiagnosis and potentially harmful medical care. A groundbreaking study has now defined pediatric reference intervals for these two common cardiovascular disease tests, which is vital for improving heart condition diagnosis and treatment in children.

Researchers at The Hospital for Sick Children (SickKids, Toronto, ON, Canada) conducted a study to establish pediatric reference intervals for both hs-cTnI and NT-proBNP. They analyzed around 200 blood samples from healthy pediatric patients (ranging from newborns to 18-year-olds) using hs-cTnI and NT-proBNP tests from a major diagnostic manufacturer. Based on the analysis results, the researchers followed the Clinical and Laboratory Standards Institute EP-28A3c guidelines to determine reference limits at the 2.5th, 97.5th, and 99th percentiles.

Importantly, the researchers discovered that hs-cTnI and NT-proBNP blood concentrations are significantly higher in newborns, with 99th percentiles at 55.8 ng/L and 1,785 ng/L, respectively. This indicates that test results for hs-cTnI and NT-proBNP not exceeding these levels are normal for newborns, although such levels in adults would suggest cardiovascular disease. This finding could prevent misdiagnosis of heart issues in newborns and highlights the importance of pediatric reference intervals for these tests.

"Lack of evidence-based pediatric reference standards for cardiac biomarker interpretation complicates test interpretation," said Khosrow Adeli, PhD, and PhD candidate Mary Kathryn Bohn of SickKids, who conducted the study. "The current study establishes comprehensive pediatric reference limits for high sensitivity cardiac troponin I and NT-proBNP in the CALIPER cohort and demonstrates the importance of considering age in interpretation. These data valuably contribute to the limited literature on expected health-associated values for cardiac biomarkers in children and will be helpful to clinical laboratories in interpreting these [increasingly] utilized assays in neonates, children, and adolescents."

Related Links:
SickKids 

Gold Member
Rickettsia Conorii Assay
RICKETTSIA CONORII ELISA
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
New
Vedolizumab ELISA
RIDASCREEN VDZ Monitoring
New
Sexually Transmitted Diseases Test
STD Panel Strip

Print article

Channels

Clinical Chemistry

view channel
Image: The new saliva-based test for heart failure measures two biomarkers in about 15 minutes (Photo courtesy of Trey Pittman)

POC Saliva Testing Device Predicts Heart Failure in 15 Minutes

Heart failure is a serious condition where the heart muscle is unable to pump sufficient oxygen-rich blood throughout the body. It ranks as a major cause of death globally and is particularly fatal for... Read more

Hematology

view channel
Image: The discovery of a new blood group has solved a 50- year-old mystery (Photo courtesy of 123RF)

Newly Discovered Blood Group System to Help Identify and Treat Rare Patients

The AnWj blood group antigen, a surface marker discovered in 1972, has remained a mystery regarding its genetic origin—until now. The most common cause of being AnWj-negative is linked to hematological... Read more

Microbiology

view channel
Image: The Accelerate WAVE system delivers rapid AST directly from positive blood culture bottles (Photo courtesy of Accelerate Diagnostics)

Rapid Diagnostic System to Deliver Same-Shift Antibiotic Susceptibility Test Results

The World Health Organization estimates that sepsis impacts around 49 million people worldwide each year, resulting in roughly 11 million deaths, with about 1.32 million of these deaths directly linked... Read more

Pathology

view channel
Image: The PAXgene Urine Liquid Biopsy Set is the first standardized preanalytical workflow that stabilizes cell-free DNA in urine for subsequent analysis (Photo courtesy of PreAnalytiX)

Liquid Biopsy Solution Enables Non-Invasive Sample Collection and Direct Cell-Free DNA Stabilization from Urine

Urine cell-free DNA (cfDNA) presents significant potential for research and future clinical applications. It facilitates the measurement and analysis of cfDNA fragments, detection of genetic alterations,... Read more

Industry

view channel
Image: International expert meeting for trends and innovations in laboratory medicine - the MEDICA LABMED FORUM at MEDICA (Photo courtesy of Constanze Tillmann/Messe Düsseldorf)

MEDICA LABMED FORUM 2024: International Experts Meet to Discuss Trending Topics in Laboratory Medicine

At MEDICA (Düsseldorf, Germany), the world’s premier trade fair for the healthcare industry and medical technology sector, this year’s event (November 11–14) will focus on the most exciting medical advancements.... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.